SkinBioTherapeutics: Directorate change

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or the “Group”)

Directorate Change

Former Procter & Gamble Senior Executive to Join SkinBioTherapeutics Board

FY26 results to be announced in November 2026

10 November 2026 – SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health announces the appointment of Gill Whitty-Collins, former Senior Vice President of P&G Beauty at Procter & Gamble, as a Non-Executive Director. She will also be Chair of the Remuneration Committee.

Gill Whitty-Collins spent 26 years with Procter & Gamble where she led global brands including Always, Pantene and Olay, and progressed through the roles of Marketing Director and General Manager to Senior Vice President. Her board experience includes a current Trustee role at 50:50 Parliament and she was a NED at Cellular Goods and Chair of Swiss Netball.

Since leaving Procter & Gamble, she has had a portfolio career, as a keynote speaker, board member, consultant and coach, drawing on her experience in business leadership, brand building and gender equality. Gill is a Fellow of the RSA (The Royal Society for Arts, Manufacturers and Commerce) and Founder of The Brand Execs. She is also the author of Why Men Win at Work and the follow-up, The How to Win at Work Book. She is a graduate of Cambridge University.

Alyson Levett, Chair of SkinBioTherapeutics plc, said:

“We are delighted to welcome Gill to the Board. She has more than two decades of experience of building and managing major consumer brands, and has a clear understanding of how to turn brand strategy into commercial results. Her experience in leadership and organisational culture will also be valuable as we continue to strengthen the business. Gill brings an important additional commercial perspective to the board and we look forward to working with her as we build on the progress made and focus on delivering the groups growth potential.”

The Company intends to report its FY26 results in November 2026 and will be issuing a notice of results in due course.

The following information is disclosed pursuant to rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:

-Ends-

Images

For more information please contact:

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life sciences company focused on skin health. The Group’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Company’s strategic approach to skin health is via two routes – tackling skin issues from the ‘outside in’ and the ‘inside out’. The ‘outside in’ approach is represented by topical creams, and from the ‘inside out’, via oral supplement solutions which impact the skin via different axes such as the gut and the brain.

SkinBio’s products and services are developed through evidence-based science and commercially focused innovation with the aim of supporting skin health, well-being, repair and beauty. SkinBio also has a contract manufacturing and distribution arm related to skin health and other healthcare products.

The Company listed on AIM in April 2017. For more information, visit: www.SkinBioTherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.